OPA1 (Optic Atrophy 1) neurons represent a classification based on expression of OPA1, a dynamin-related GTPase essential for mitochondrial inner membrane fusion and cristae maintenance. OPA1 mutations cause autosomal dominant optic atrophy (ADOA), the most common inherited optic neuropathy. Beyond the visual system, OPA1 dysfunction contributes to neurodegeneration in Alzheimer's disease, Parkinson's disease, and other disorders affecting neurons with high metabolic demands.[1]
The OPA1 gene is located on chromosome 3q29 and encodes a 960-amino acid dynamin-related GTPase:[2]
| Domain | Position | Function |
|---|---|---|
| MTS | 1-30 | Mitochondrial targeting sequence |
| GTPase | 260-580 | GTP binding and hydrolysis |
| Middle | 580-750 | Oligomerization |
| GED | 750-960 | GTPase effector domain |
OPA1 exists in multiple isoforms generated by alternative splicing and proteolytic processing:[3]
Long forms (L-OPA1):
Short forms (S-OPA1):
Processing proteases:
OPA1 maintains cristae junction integrity:[4]
Cristae morphology:
Respiratory chain assembly:
Neurons are particularly dependent on OPA1:[5]
High ATP demand regions:
Calcium buffering:
OPA1 has dual roles in cell survival:[6]
Anti-apoptotic:
Pro-apoptotic cleavage:
ADOA is the prototype OPA1 disorder:[7]
Clinical features:
Pathophysiology:
OPA1 mutations:
400 pathogenic variants identified
ADOA-plus syndrome:
OPA1 dysfunction contributes to AD pathology:[8]
Mitochondrial fragmentation:
Therapeutic implications:
OPA1 intersects with PD pathways:[9]
PINK1/Parkin pathway:
Dopaminergic neuron vulnerability:
Lewy body mitochondria:
Huntington's disease:
ALS:
| Approach | Mechanism | Status |
|---|---|---|
| AAV-OPA1 | Gene augmentation | Phase I/II |
| Stem cell RGC | Cell replacement | Preclinical |
| CRISPR base editing | Mutation correction | Research |
OPA1 stabilizers:
Mitochondrial support:
OPA1 neurons highlight the critical role of mitochondrial dynamics in neurodegeneration. OPA1 maintains cristae integrity, respiratory efficiency, and prevents apoptosis. Mutations cause ADOA, while secondary dysfunction contributes to AD, PD, HD, and ALS. Restoring OPA1-mediated fusion represents a promising therapeutic strategy for mitochondrial neurodegeneration.
Amati-Bonneau P, Valentino ML, Reynier P, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes. Brain. 2008. ↩︎
Delettre C, Lenaers G, Griffoin JM, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nature Genetics. 2000. ↩︎
Anand R, Wai T, Baker MJ, et al. The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission. Journal of Cell Biology. 2014. ↩︎
Frezza C, Cipolat S, de Brito OM, et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell. 2006. ↩︎
Williams PA, Morgan JE, Votruba M. OPA1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy. Brain. 2010. ↩︎
Jiang X, Jiang H, Shen Z, Wang X. Increased activation of the mitochondrial apoptotic pathway in the optic nerve of OPA1 mutant mice. Journal of Neurochemistry. 2013. ↩︎
Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies – disease mechanisms and therapeutic strategies. Progress in Retinal and Eye Research. 2011. ↩︎
Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. Journal of Neuroscience. 2009. ↩︎
Müller-Ribeiro FC, Zampieri LC, Nogueira BS, et al. OPA1 overexpression enhances mitochondrial function and protects against neurodegeneration in Parkinson's models. Neurobiology of Disease. 2019. ↩︎